Overview

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Etoricoxib